We also clinically validated our findings by demonstrating a correlation between the nuclear localization of GR and MAST1 expression levels as well as cisplatin resistance in primary tumor tissue samples collected from cancer patients before and after treatment with platinum-containing regimens. This evidence concerns the gene NR3C1 and cancer.